AbCellera focuses on therapeutic antibodies, screening, choosing, and analyzing millions of naturally produced antibodies to be used as next-generation drug candidates. It specializes in the fields of biotechnology, medicine, and therapeutics.

BioRender is revolutionizing how science is communicated, one graphic at a time (you can think of us as the Adobe or Canva for science!). We're on a mission to accelerate science by empowering all scientists to quickly and easily communicate their research.

Cyclica is the partner of choice for data-driven drug discovery. We advance molecules that embrace the complexity of disease. Our computational approach to polypharmacology is unique in the industry. Screening for actives with target-specific black boxes has limited upside. Instead, we use a proteome-wide lens to evaluate multiple novel and rare on and off-target interactions simultaneously. We’re also the only company of our kind that integrates science to advance molecules downstream. A structure-based view keeps our work accountable to biology, chemistry, physics, and genomics. Not all hits are created equal. Our commitment to collaborating holistically improves the odds of reaching milestones dramatically. For our large biotech and pharma customers, we help enrich existing portfolios, building custom models that deliver IP-grade, proprietary insights with breakthrough efficiency and precision. Separately, across a portfolio of more than 50 joint ventures and growing, we work at the vanguard of a wide variety of therapeutic areas to help get new medicines to patients faster and more precisely. To learn more about Cyclica and how we partner, please visit www.cyclicarx.com Cyclica. From molecule to medicine.

Deep Genomics recruits from among the top 1% of recent graduates and seasoned experts at the intersection of genomics, drug development and AI.

Gandeeva Therapeutics has developed a proprietary platform that combines innovative technologies across biochemistry, structural biology, imaging and machine learning to characterize protein-drug interactions at the atomic level, all designed to provide new insights into targeting protein function.

Membio is on a mission to ensure the world has a safe and sufficient supply of blood. Globally, only 40% of the world's need for blood is able to be supplied from the current donation system, leaving over $60+ Billion in unfulfilled market demand. Even in the USA, there is a perpetual shortage for universally accepted O negative blood. At Membio we are developing a viable and scalable alternative to the donation system. By cost-effective manufacturing red blood cells outside the body, we are able to produce an unlimited amount of transfusion quality RBCs while eliminating donor recruitment and blood collection, testing, and processing. Our fully functional better than O negative RBCs increase patient safety by having reduced immunogenicity and being pathogen and toxin-free. These superior quality RBCs from specialized cell lines and are grown in our novel manufacturing system. This manufacturing system combines scalability with microenvironment to achieve cost-effective production on an industrial scale."

Nomic develops a proteomic technology platform designed to understand, detect, and treat diseases with DNA nanotechnology. NPlex's platform and research provides cost-effective measurement of protein data with sample, fits seamlessly within industry cytometers for high-throughput analysis, and development of custom protein panels. It allows nanotechnology developers and businesses to bring improvement in existing instrument, workflow, and bring automation in the system.

Phenomic AI is a developer of a drug discovery platform designed to discovery and optimize therapeutics directly against phenotypic assays.The company's platform uses artificial intelligence to analyze phenotypes in complex disease models including high-content co-culture and 3D assays, enabling pharmaceutical companies to discover drugs in an easier way.

ProteinQure is a Toronto-based startup building a computational platform for design of protein therapeutics. Our mission is to help to create a world where drugs are engineered, not discovered. We work on treatments for cancer, diabetes, asthma, and cardiovascular diseases, among others, and partner with industry leaders in drug discovery to generate novel therapeutics outside of the conventional chemical space.

Valence Discovery is building the world’s most powerful chemistry engine. The company has pioneered the application of few-shot learning in drug design, along with the development of best-in-class AI methods for molecular representation, structure and ligand-based de novo design, and multiparameter optimization, enabling the design of novel chemistry against previously intractable biology.